journal
MENU ▼
Read by QxMD icon Read
search

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

journal
https://www.readbyqxmd.com/read/28649597/early-diagnosis-of-mild-cognitive-impairment-and-alzheimer-s-disease-based-on-salivary-lactoferrin
#1
Eva Carro, Fernando Bartolomé, Félix Bermejo-Pareja, Alberto Villarejo-Galende, José Antonio Molina, Pablo Ortiz, Miguel Calero, Alberto Rabano, José Luis Cantero, Gorka Orive
INTRODUCTION: The Alzheimer's disease (AD) process is likely initiated many years before clinical onset. Biomarkers of preclinical disease are critical for the development of disease-modifying or even preventative therapies. Current biomarkers for early disease, including cerebrospinal fluid tau and amyloid β (Aβ) levels, structural and functional magnetic resonance imaging, and the use of brain amyloid imaging, are limited because they are very invasive or expensive. Noninvasive biomarkers may be a more accessible alternative, but none can currently detect preclinical AD with the required sensitivity and specificity...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28649596/phenoconversion-from-probable-rapid-eye-movement-sleep-behavior-disorder-to-mild-cognitive-impairment-to-dementia-in-a-population-based-sample
#2
Youngsin Jung, Brendon P Boot, Michelle M Mielke, Tanis J Ferman, Yonas E Geda, Eric McDade, Teresa J H Christianson, David S Knopman, Erik K St Louis, Michael H Silber, Ronald C Petersen, Bradley F Boeve
INTRODUCTION: Rapid eye movement sleep behavior disorder (RBD) is strongly associated with synucleinopathies. In 2012, we reported an increased risk of mild cognitive impairment (MCI) and Parkinson disease (PD) in cognitively normal Olmsted County, Minnesota, residents, aged 70 to 89 years with probable RBD. Here, we examine their progression to dementia and other neurodegenerative phenotypes. METHODS: Fifteen participants with RBD who were diagnosed with either MCI or PD were longitudinally followed, and their subsequent clinical courses were reviewed...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28603769/longitudinal-changes-in-amyloid-positron-emission-tomography-and-volumetric-magnetic-resonance-imaging-in-the-nondemented-down-syndrome-population
#3
Patrick J Lao, Ben L Handen, Tobey J Betthauser, Iulia Mihaila, Sigan L Hartley, Annie D Cohen, Dana L Tudorascu, Peter D Bulova, Brian J Lopresti, Rameshwari V Tumuluru, Dhanabalan Murali, Chester A Mathis, Todd E Barnhart, Charles K Stone, Julie C Price, Darlynne A Devenny, Marsha R Mailick, William E Klunk, Sterling C Johnson, Bradley T Christian
INTRODUCTION: Down syndrome (DS) arises from a triplication of chromosome 21, causing overproduction of the amyloid precursor protein and predisposes individuals to early Alzheimer's disease (AD). METHODS: Fifty-two nondemented adults with DS underwent two cycles of carbon 11-labeled Pittsburgh compound B ([(11)C]PiB) and T1 weighted magnetic resonance imaging (MRI) scans 3.0 ± 0.6 years apart. Standard uptake value ratio (SUVR) images (50-70 minutes; cerebellar gray matter [GM]) and GM volumes were analyzed in standardized space (Montreal Neurological Institute space)...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28603768/consensus-guidelines-for-lumbar-puncture-in-patients-with-neurological-diseases
#4
Sebastiaan Engelborghs, Ellis Niemantsverdriet, Hanne Struyfs, Kaj Blennow, Raf Brouns, Manuel Comabella, Irena Dujmovic, Wiesje van der Flier, Lutz Frölich, Daniela Galimberti, Sharmilee Gnanapavan, Bernhard Hemmer, Erik Hoff, Jakub Hort, Ellen Iacobaeus, Martin Ingelsson, Frank Jan de Jong, Michael Jonsson, Michael Khalil, Jens Kuhle, Alberto Lleó, Alexandre de Mendonça, José Luis Molinuevo, Guy Nagels, Claire Paquet, Lucilla Parnetti, Gerwin Roks, Pedro Rosa-Neto, Philip Scheltens, Constance Skårsgard, Erik Stomrud, Hayrettin Tumani, Pieter Jelle Visser, Anders Wallin, Bengt Winblad, Henrik Zetterberg, Flora Duits, Charlotte E Teunissen
INTRODUCTION: Cerebrospinal fluid collection by lumbar puncture (LP) is performed in the diagnostic workup of several neurological brain diseases. Reluctance to perform the procedure is among others due to a lack of standards and guidelines to minimize the risk of complications, such as post-LP headache or back pain. METHODS: We provide consensus guidelines for the LP procedure to minimize the risk of complications. The recommendations are based on (1) data from a large multicenter LP feasibility study (evidence level II-2), (2) systematic literature review on LP needle characteristics and post-LP complications (evidence level II-2), (3) discussion of best practice within the Joint Programme Neurodegenerative Disease Research Biomarkers for Alzheimer's disease and Parkinson's Disease and Biomarkers for Multiple Sclerosis consortia (evidence level III)...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28603767/lumbar-puncture-in-patients-with-neurologic-conditions
#5
Rosha Babapour Mofrad, Femke H Bouwman, Rosalinde E R Slot, Tessa Timmers, Wiesje M van der Flier, Philip Scheltens, Charlotte E Teunissen
A lumbar puncture is performed to obtain cerebral spinal fluid. It is implemented in the clinic on a routine basis to aid the diagnosis of neurologic diseases, such as dementia. This video will show the lumbar puncture procedure as routinely performed in the VUmc Alzheimer Center.
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28560310/longitudinal-evaluation-of-criteria-for-subjective-cognitive-decline-and-preclinical-alzheimer-s-disease-in-a-memory-clinic-sample
#6
Marie Eckerström, Mattias Göthlin, Sindre Rolstad, Erik Hessen, Carl Eckerström, Arto Nordlund, Boo Johansson, Johan Svensson, Michael Jonsson, Simona Sacuiu, Anders Wallin
INTRODUCTION: Subjective cognitive decline (SCD) and biomarker-based "at-risk" concepts such as "preclinical" Alzheimer's disease (AD) have been developed to predict AD dementia before objective cognitive impairment is detectable. We longitudinally evaluated cognitive outcome when using these classifications. METHODS: Memory clinic patients (n = 235) were classified as SCD (n = 122): subtle cognitive decline (n = 36) and mild cognitive impairment (n = 77) and subsequently subclassified into SCDplus and National Institute on Aging-Alzheimer's Association (NIA-AA) stages 0 to 3...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28560309/single-nucleotide-polymorphisms-are-associated-with-cognitive-decline-at-alzheimer-s-disease-conversion-within-mild-cognitive-impairment-patients
#7
Eunjee Lee, Kelly S Giovanello, Andrew J Saykin, Fengchang Xie, Dehan Kong, Yue Wang, Liuqing Yang, Joseph G Ibrahim, P Murali Doraiswamy, Hongtu Zhu
INTRODUCTION: The growing public threat of Alzheimer's disease (AD) has raised the urgency to quantify the degree of cognitive decline during the conversion process of mild cognitive impairment (MCI) to AD and its underlying genetic pathway. The aim of this article was to test genetic common variants associated with accelerated cognitive decline after the conversion of MCI to AD. METHODS: In 583 subjects with MCI enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI; ADNI-1, ADNI-Go, and ADNI-2), 245 MCI participants converted to AD at follow-up...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28560308/resting-state-network-dysfunction-in-alzheimer-s-disease-a-systematic-review-and-meta-analysis
#8
AmanPreet Badhwar, Angela Tam, Christian Dansereau, Pierre Orban, Felix Hoffstaedter, Pierre Bellec
INTRODUCTION: We performed a systematic review and meta-analysis of the Alzheimer's disease (AD) literature to examine consistency of functional connectivity alterations in AD dementia and mild cognitive impairment, using resting-state functional magnetic resonance imaging. METHODS: Studies were screened using a standardized procedure. Multiresolution statistics were performed to assess the spatial consistency of findings across studies. RESULTS: Thirty-four studies were included (1363 participants, average 40 per study)...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28508031/altered-levels-of-blood-proteins-in-alzheimer-s-disease-longitudinal-study-results-from-australian-imaging-biomarkers-lifestyle-study-of-ageing-cohort
#9
Veer Bala Gupta, Eugene Hone, Steve Pedrini, James Doecke, Sid O'Bryant, Ian James, Ashley I Bush, Christopher C Rowe, Victor L Villemagne, David Ames, Colin L Masters, Ralph N Martins
INTRODUCTION: A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing. METHODS: We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort. RESULTS: Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P = ...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28492059/severity-of-memory-impairment-in-the-elderly-association-with-health-care-resource-use-and-functional-limitations-in-the-united-states
#10
Myrlene Sanon Aigbogun, Robert Stellhorn, Holly Krasa, Dusan Kostic
INTRODUCTION: Dementia is a prevalent condition in older adults associated with decline in cognitive and functional abilities and substantial burden. This study assessed the prevalence and impact of subjective memory impairment in the United States. METHODS: The 2011 to 2014 National Health and Nutrition Examination Survey, a population-based, nationally representative survey, was analyzed. Data included medical examinations, self-reported cognitive and functional limitations, and health care utilization over 1 year...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28462389/effect-of-long-term-storage-in-biobanks-on-cerebrospinal-fluid-biomarker-a%C3%AE-1-42-t-tau-and-p-tau-values
#11
Eline A J Willemse, Kees W J van Uffelen, Wiesje M van der Flier, Charlotte E Teunissen
INTRODUCTION: We studied the effect of long-term storage at -80°C on cerebrospinal fluid (CSF) biomarker levels. Our approach assumed consistency of mean biomarker levels in a homogenous Alzheimer's disease patient cohort over time. METHODS: We selected 148 Alzheimer's disease samples that had inclusion dates equally distributed over the years 2001 to 2013 from our biobank. The concentrations of CSF biomarkers, amyloid β1-42 (Aβ1-42), total tau (T-tau), and phosphorylated tau181 (P-tau), were measured with one enzyme-linked immunosorbent assay lot...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28462388/multidimensional-assessment-of-challenging-behaviors-in-advanced-stages-of-dementia-in-nursing-homes-the-insidedem-framework
#12
Stefan Teipel, Christina Heine, Albert Hein, Frank Krüger, Andreas Kutschke, Sven Kernebeck, Margareta Halek, Sebastian Bader, Thomas Kirste
INTRODUCTION: Assessment of challenging behaviors in dementia is important for intervention selection. Here, we describe the technical and experimental setup and the feasibility of long-term multidimensional behavior assessment of people with dementia living in nursing homes. METHODS: We conducted 4 weeks of multimodal sensor assessment together with real-time observation of 17 residents with moderate to very severe dementia in two nursing care units. Nursing staff received extensive training on device handling and measurement procedures...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28462387/detecting-functional-decline-from-normal-aging-to-dementia-development-and-validation-of-a-short-version-of-the-amsterdam-iadl-questionnaire
#13
Roos J Jutten, Carel F W Peeters, Sophie M J Leijdesdorff, Pieter Jelle Visser, Andrea B Maier, Caroline B Terwee, Philip Scheltens, Sietske A M Sikkes
INTRODUCTION: Detecting functional decline from normal aging to dementia is relevant for diagnostic and prognostic purposes. Therefore, the Amsterdam IADL Questionnaire (A-IADL-Q) was developed: a 70-item proxy-based tool with good psychometric properties. We aimed to design a short version while preserving its psychometric quality. METHODS: Study partners of subjects (n = 1355), ranging from cognitively normal to dementia subjects, completed the original A-IADL-Q...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28435852/changes-in-metabolic-risk-factors-over-10%C3%A2-years-and-their-associations-with-late-life-cognitive-performance-the-multi-ethnic-study-of-atherosclerosis
#14
Timothy M Hughes, Suzanne Craft, Laura D Baker, Mark A Espeland, Stephen R Rapp, Kaycee M Sink, Alain G Bertoni, Gregory L Burke, Rebecca F Gottesman, Erin D Michos, José A Luchsinger, Annette L Fitzpatrick, Kathleen M Hayden
BACKGROUND: We examined whether changes in metabolic factors over 10 years were associated with cognitive performance. METHODS: Participants from the Multi-Ethnic Study of Atherosclerosis were followed since baseline (2000-2002) with five clinical examinations. At exam 5 (2010-2012), they received a short cognitive battery (Cognitive Abilities Screening Instrument [CASI], Digit Symbol Coding [DSC], and Digit Span [DS]). We examined associations between baseline metabolic factors and their changes over time before cognitive testing...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28435851/choroidal-thinning-alzheimer-s-disease-and-aging
#15
João Paulo Cunha, Rita Proença, Arnaldo Dias-Santos, Diana Melancia, Rita Almeida, Helena Águas, Bruno Oliveira Santos, Marta Alves, Joana Ferreira, Ana Luísa Papoila, Carlota Louro, António Castanheira-Dinis
INTRODUCTION: The purpose of this study was to measure and to compare macular choroidal thickness (CT) between patients with mild Alzheimer's disease (AD), patients without AD, and elderly patients. METHODS: CT was measured manually in 13 locations at 500-μm intervals of a horizontal and a vertical section from the fovea. Linear regression models were used to analyze the data. RESULTS: Fifty patients with a diagnosis of mild AD (73.1 years), 152 patients without AD (71...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28413821/cerebrospinal-fluid-biomarkers-for-alzheimer-s-disease-in-down-syndrome
#16
Alain D Dekker, Juan Fortea, Rafael Blesa, Peter P De Deyn
Down syndrome (DS), present in nearly six million people, is associated with an extremely high risk to develop Alzheimer's disease (AD). Amyloid-β and tau pathology are omnipresent from age 40 years onward, but clinical symptoms do not appear in all DS individuals. Dementia diagnostics is complex in this population, illustrating the great need for predictive biomarkers. Although blood biomarkers have not yet proven useful, cerebrospinal fluid (CSF) biomarkers (low amyloid-β42, high t-tau, and high p-tau) effectively contribute to AD diagnoses in the general population and are increasingly used in clinical practice...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28393099/reduced-future-oriented-decision-making-in-individuals-with-subjective-cognitive-decline-a-functional-mri-study
#17
Xiaochen Hu, Franziska Uhle, Klaus Fliessbach, Michael Wagner, Ying Han, Bernd Weber, Frank Jessen
INTRODUCTION: Subjective cognitive decline (SCD) refers to an at-risk state of Alzheimer's disease and subtle cognitive deficits that have been observed in this condition. Currently, it is unknown whether complex cognitive processes relevant to everyday life, such as future-oriented choice behavior, are also altered in SCD. METHODS: Twenty SCD participants and 24 control (CO) participants took part in a functional magnetic resonance imaging task on intertemporal decisions, with and without simultaneous episodic future imagination...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28378011/%C3%AE-scores-predict-mild-cognitive-impairment-and-alzheimer-s-disease-conversions-from-nondemented-states
#18
Donald R Royall, Raymond F Palmer
INTRODUCTION: We tested the latent variable "δ" (for "dementia")'s ability to predict conversion to "mild cognitive impairment" (MCI) and Alzheimer's disease (AD). METHODS: An ethnicity equivalent d homolog ("dEQ") was constructed in n = 1113 Mexican- American (MA) and n = 1958 non-Hispanic white (NHW) participants in the Texas Alzheimer's Research and Care Consortium. "Normal Controls" (NC) (n = 1276) and MCI cases (n = 611) were followed annually for up to 6 years [m = 4...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28349120/variability-in-medication-taking-is-associated-with-cognitive-performance-in-nondemented-older-adults
#19
Johanna Austin, Krystal Klein, Nora Mattek, Jeffrey Kaye
Interventions to slow cognitive decline typically can do little to reverse decline. Thus, early detection methods are critical. However, tools like cognitive testing are time consuming and require costly expertise. Changes in activities of daily living such as medication adherence may herald the onset of cognitive decline before clinical standards. Here, we determine the relationship between medication adherence and cognitive function in preclinical older adults. We objectively assessed medication adherence in 38 older adults (mean age 86...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28349119/a-multinational-study-distinguishing-alzheimer-s-and-healthy-patients-using-cerebrospinal-fluid-tau-a%C3%AE-42-cutoff-with-concordance-to-amyloid-positron-emission-tomography-imaging
#20
Yi Mo, Julie Stromswold, Kimberly Wilson, Daniel Holder, Cyrille Sur, Omar Laterza, Mary J Savage, Arie Struyk, Philip Scheltens, Charlotte E Teunissen, James Burke, S Lance Macaulay, Geir Bråthen, Sigrid Botne Sando, Linda R White, Christy Weiss, Arturo Cowes, Michele M Bush, Ganga DeSilva, David G Darby, Stephanie R Rainey-Smith, Jackie Surls, Eileen Sagini, Michael Tanen, Amy Altman, Johan Luthman, Michael F Egan
INTRODUCTION: Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development of Alzheimer's brain pathology. Robust tau and Aβ42 immunoassays were developed to establish a tau/Aβ42 cutoff distinguishing mild-to-moderate Alzheimer's disease (AD) subjects from healthy elderly control (HC) subjects. METHODS: A CSF tau/Aβ42 cutoff criteria was chosen, which distinguished the groups and maximized concordance with amyloid PET. Performance was assessed using an independent validation cohort...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
journal
journal
50108
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"